Highest-materiality recent filing
Exclusive U.S. distribution rights for MyoSleeve within VA and DoD systems.
Tactile Systems shareholders approve director removal amendment, re-elect all directors
Stockholders approved amendment to allow director removal consistent with Delaware law; 14.9M For, 0.9M Against.
Tactile Medical Q1 revenue up 23% to $75.3M; net loss narrows to $1.8M; raises FY2026 guidance
Revenue $75.3M (+23% YoY); lymphedema +23%, airway clearance +22%.
Tactile Medical appoints Andrea Pearson to Board of Directors effective March 9, 2026
Pearson joins board and serves on Compliance & Reimbursement and Nominating & Corporate Governance committees.
Tactile Medical Q4 revenue up 21% to $103.6M; acquires LymphaTech for $6.8M
Q4 2025 revenue $103.6M (+21% YoY); net income $10.6M ($0.46 diluted EPS) vs $9.7M ($0.40) in Q4 2024.
Tactile Medical Q3 net income $8.2M, revenue up 17%; raises FY guidance and authorizes $25M buyback
Q3 revenue $85.8M (+17% YoY), net income $8.2M ($0.36 diluted EPS) vs $5.2M ($0.21) in Q3 2024.
Revenue $78.9M, up 7.8% YoY, ahead of prior expectations; gross margin improved to 75% from 74%.
Stockholders approve 2025 Equity Incentive Plan with 1.85M new shares; all board nominees elected
2025 Equity Incentive Plan approved, authorizing up to 1,850,000 new shares of common stock.
Tactile Medical Q1 revenue flat, net loss widens; lowers FY 2025 revenue and EBITDA guidance
Q1 2025 revenue $61.3M (+0.3% YoY); net loss $3.0M vs $2.2M loss in Q1 2024.
Tactile Medical Q4 rev $85.6M (+10%), net income $9.7M; guides FY25 rev $316-322M
Q4 total revenue $85.6M (+10% YoY); gross margin 75.2% vs 72.1% YoY.
Tactile Medical appoints Laura King to Board of Directors effective Jan 13, 2025
Laura King elected to Board; serves on Audit and Compliance & Reimbursement Committees.
Tactile Medical Q3 revenue up 5% to $73.1M; guides FY2024 $292-295M, authorizes $30M buyback
Q3 revenue $73.1M (+5% YoY); lymphedema +4%, airway clearance +10%.
Tactile Medical Q2 revenue $73.2M (+7% YoY); lowers FY 2024 guidance to $293-298M
Revenue of $73.2M, up 7% YoY; lymphedema product revenue +8%, airway clearance +2%.
Enters Stipulation of Settlement in derivative lawsuit Weaver v. Moen, dated June 6, 2024.
Tactile Systems stockholders approve officer exculpation amendment at 2024 annual meeting
All eight director nominees elected; Valerie Asbury with 17.8M votes for, 442k withheld.
TCMD Q1 revenue up 4% to $61.1M, net loss $2.2M; reaffirms FY2024 outlook; CEO transition
Total revenue $61.1M (+4% YoY); lymphedema +5%, airway clearance -4%.
Tactile Medical CEO transition and preliminary Q1 revenue ~$61M
CEO Dan Reuvers to retire June 30, 2024; Sheri Dodd appointed CEO effective July 1, 2024.
Q4 2023 revenue $77.7M (+5% YoY); net income $8.2M (+77%); diluted EPS $0.35 vs $0.23.
Tactile Medical Q3 revenue $69.6M (+7% YoY); net income $22.3M vs loss; updates FY guidance
Revenue $69.6M, up 7% YoY; lymphedema +15%, airway clearance -36%.
Tactile Medical appoints Dr. Vindell Washington to board of directors effective Oct 2, 2023
Appointed Vindell Washington, M.D. to board effective Oct 2, 2023; brings 30+ years healthcare experience.
Tactile Medical Q2 revenue $68.3M (+15% YoY); narrows net loss to $0.1M; raises FY23 guidance
Revenue $68.3M (+15% YoY); lymphedema +16%, airway clearance +4%.
Tactile Medical appoints Sherri Ferstler SVP Sales; Eric Pauls resigns
Eric Pauls resigns as SVP Sales effective July 28, 2023.
Tactile Systems stockholders elect all seven director nominees at 2023 annual meeting
Valerie L. Asbury, William W. Burke, Sheri L. Dodd, Raymond O. Huggenberger, Daniel L. Reuvers, D. Brent Shafer, and Carmen B. Volkart elected to one-year terms.
Tactile Medical Q1 revenue up 23% to $58.8M; raises FY2023 guidance to $271-275M
Q1 revenue $58.8M (+23% YoY); net loss narrowed to $1.9M ($0.09 diluted) from $15.6M loss ($0.78).
Tactile Medical appoints Elaine Birkemeyer as CFO, effective March 20, 2023
Birkemeyer succeeds retiring CFO Brent Moen; brings 26 years of finance experience from UnitedHealth Group and Best Buy.
Tactile Medical prices $32.5M public offering of 2.5M shares at $13.00/share
Gross proceeds of $32.5M from 2,500,000 shares at $13.00 per share.
Tactile Medical Q4 revenue up 20% to $73.9M; CFO Brent Moen to retire in 2023
Q4 2022 revenue $73.9M (+20% YoY); lymphedema +14%, airway clearance +90%.
Tactile Medical appoints Carmen Volkart to Board of Directors effective Jan 5, 2023
Carmen Volkart elected to board; board size fixed at eight directors as of Jan 5, 2023.
Tactile Systems amends bylaws to implement Rule 14a-19 director nomination procedures
Stockholders must certify compliance with Rule 14a-19 and provide evidence five business days before the meeting.
Tactile Systems posts updated November 2022 investor presentation; no new financial data
Updated investor presentation filed as Exhibit 99.1; posted on company website.
Tactile Medical Q3 revenue up 24% to $65.3M; raises FY2022 guidance
Q3 revenue $65.3M (+24% YoY); net loss $2.3M ($0.11/sh) vs loss $3.4M ($0.17) a year ago.
Tactile Medical Q2 revenue $59.6M (+17% YoY); raises FY22 revenue guidance to $238-242M
Net loss $4.6M ($0.23/share) vs net income $1.3M ($0.07) in Q2 2021; adjusted EBITDA $1.7M vs $4.1M.
Tactile Systems stockholders elect all director nominees, ratify auditor, approve say-on-pay
All seven director nominees elected: Valerie L. Asbury, William W. Burke, Sheri L. Dodd, Raymond O. Huggenberger, Deepti Jain, Daniel L. Reuvers, D. Brent Shafer.
Tactile Medical Q1 revenue $48.0M (+12% YoY); net loss $15.6M vs $2.3M loss YoY
Revenue $48.0M (+12% YoY); net loss $15.6M ($0.78 diluted EPS) vs $2.3M ($0.12) in Q1 2021.
Tactile Medical announces qui tam lawsuit against it dropped and dismissed without payment
Competitor-filed qui tam lawsuit challenging patient/physician education programs dismissed by federal judge in Texas.
Tactile Medical Q4 rev $61.7M (+4% YoY); net loss $7.5M; FY 2022 guidance $235-240M
Q4 revenue $61.7M (+4% YoY); full year 2021 revenue $208.1M (+11% YoY).
Valerie Asbury (CEO of LifeScan) and D. Brent Shafer (ex-Cerner CEO) join board effective Jan 5, 2022.
Tactile Medical Q3 revenue $52.5M (+7% YoY), net loss $3.4M; cuts FY2021 guidance to $203.5-206M
Q3 revenue $52.5M (+7% YoY); net loss $3.4M ($0.17/share) vs net income $2.4M ($0.12) in Q3 2020.
Acquired AffloVest HFCWO vest business from International Biophysics Corp for $80M cash, with up to $20M in earn-outs based on 12-month revenue targets.
Tactile Medical Q2 revenue up 45% to $51.1M, net income $1.3M; raises FY guidance low end
Q2 revenue $51.1M (+45% YoY); net income $1.3M vs loss of $13.9M; diluted EPS $0.07 vs loss of $0.72.
the board of directors of Tactile Systems Technology, Inc. (the “Company”) elected Laura G. King to serve as a member of the board and fixed the size of the board at nine directors, all effective as of January 13, 2025.
the Board of Directors has appointed Sheri L. Dodd as the Company’s Chief Executive Officer, effective July 1, 2024
Daniel L. Reuvers has informed the Company’s Board of Directors of his decision to retire as Chief Executive Officer, effective as of June 30, 2024
On October 2, 2023, the board of directors of Tactile Systems Technology, Inc. (the “Company”) elected Vindell Washington, M.D. to serve as a member of the board
On July 14, 2023, Eric Pauls, the Senior Vice President, Sales of Tactile Systems Technology, Inc. (the “Company”), notified the Company of his resignation from the Company, effective July 28, 2023.
The Company’s Board of Directors has appointed Sherri Ferstler to succeed Mr. Pauls as the Company’s Senior Vice President, Sales, effective July 31, 2023.
Board of Directors has appointed Elaine M. Birkemeyer as the Company’s Chief Financial Officer, effective March 20, 2023
who is retiring as our Chief Financial Officer as previously disclosed
On February 20, 2023, Brent Moen, the Company’s Chief Financial Officer, notified the Company of his intention to retire as Chief Financial Officer in 2023.
On January 5, 2023, the board of directors of Tactile Systems Technology, Inc. (the “Company”) elected Carmen B. Volkart to serve as a member of the board and fixed the size of the board at eight directors, all effective as of January 5, 2023 .
Also on January 5, 2022, current directors Richard Nigon, Kevin Roche and Peter Soderberg notified the board that they would not be standing for re-election at the 2022 annual meeting of stockholders.
Also on January 5, 2022, current directors Richard Nigon, Kevin Roche and Peter Soderberg notified the board that they would not be standing for re-election at the 2022 annual meeting of stockholders.
Max materiality 0.85 · Median 0.65 · Most common event earnings